APVONasdaqPharmaceutical PreparationsFiscal year ends December 31
Aptevo Therapeutics Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$1.60−0.02 (-1.23%)
Close on Oct 19, 2026
- Market cap
- $1.91M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$26.84 (−94.37%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.EarningsSplit
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $1.91M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.32
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$26.41M
- EPS, diluted
- -$87.27
- Book value per share
- $5.05
- Diluted shares
- 1M
Twelve years at a glance
Fiscal years 2014 to 2025 and trailing twelve months, USD
Revenue
–
Gross profit
–
Operating income
-$26.89M
Net income
-$26.41M
EPS, diluted
–
Free cash flow
–
Reported periodTrailing twelve months